Pathology Data-Based Risk Group Stratification is Equivalent to That Obtained by Oncotype DX Testing in Prostatic Adenocarcinoma

• Published in: Archives of pathology & laboratory medicine (1976) Vol. 147; no. 10; pp. 1158 - 1163
• Main Authors: Renavikar, Pranav S, LaGrange, Chad A, Lele, Subodh M
• Format: Journal Article
• Language: English
• Published: United States College of American Pathologists 01.10.2023
• Subjects: Adenocarcinoma; Analysis; Androgens; Antigens; Biopsy; Biopsy, Needle; Cancer therapies; Care and treatment; Erectile dysfunction; Gene expression; Genetic aspects; Genomics; Health risk assessment; Immune system; Magnetic resonance imaging; Medical research; Medicine, Experimental; Methods; Pathology; Polymerase chain reaction; Prognosis; Prostate cancer; Prostate carcinoma; Radiation; Risk assessment; Surveillance; Testing; Therapeutic applications; Urinary incontinence; United States
• ISSN: 0003-9985; 1543-2165; 1543-2165
• DOI: 10.5858/ARPA.2022-0225-OA

Low-risk (Gleason score 3 + 3 = 6) and intermediate-risk (Gleason score 3 + 4 = 7) prostate carcinoma cases diagnosed on needle biopsies are frequently referred for gene expression studies such as Oncotype DX to help validate the risk. Risk assessment helps determining prognosis and therapeutic decision making. To determine if addition of molecular testing is necessary, by evaluating its correlation with risk stratification provided by pathology report (Gleason score, grade group, proportion of positive cores) and serum prostate-specific antigen (PSA) level. Our institutional database was searched for cases that had Oncotype DX testing after prostate biopsy. The final risk category determined by molecular testing was compared to the risk stratification predicted by the pathology report and serum PSA levels. Cases were classified as concordant if they fell under the same National Comprehensive Cancer Network risk and recommended initial therapy group. Follow-up information on discordant cases was obtained and used to determine if risk stratification by molecular testing was superior to that obtained from the clinicopathologic data. A total of 4967 prostate biopsies (2015-2020) were screened. Of these, 131 prostate carcinoma cases (2.6%) had Oncotype DX testing and 111 of 131 cases (85%) had follow-up information. There was risk stratification concordance in 93 of 111 cases (84%). All 18 of 111 cases (16%) that were discordant had a follow-up course that matched the risk predicted by pathology data and serum PSA. Risk stratification provided by information in the pathology report on routine biopsy assessment coupled with the serum PSA level is equivalent to that obtained by Oncotype DX testing.